metricas
covid
Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Primary small bowel adenocarcinoma
Journal Information
Vol. 85. Issue 6.
Pages 354-359 (June 2009)
Share
Share
Download PDF
More article options
Vol. 85. Issue 6.
Pages 354-359 (June 2009)
Full text access
Primary small bowel adenocarcinoma
Adenocarcinoma primario de intestino delgado
Visits
1338
Jaime Ruiz-Tovar
Corresponding author
jruiztovar@gmail.com

Author for correspondence.
, Enrique Martínez-Molina, Vicente Morales, Alfonso Sanjuanbenito
Departamento de Cirugía General y del Aparato Digestivo, Hospital Universitario Ramón y Cajal, Madrid, Spain
This item has received
Article information
Abstract
Introduction

Primary small bowel adenocarcinoma is an uncommon tumour, with nonspecific symptoms that cause a delay in the diagnosis and consequently a worse outcome for the patient. We analyse our experience in the management of this disease.

Material and method

We performed a retrospective study of our experience with 17 patients diagnosed with primary small bowel adenocarcinoma, excluding all the cases suggesting secondary involvement of the small bowel from an adenocarcinoma in other locations.

Results

We analysed 9 females (53%) and 8 males (47%) with a mean age of 61.8 years. Tumour location was duodenum (8 cases), jejunum (5), and ileum (4). Those with duodenal tumours underwent 4 pancreaticoduodenectomies, 3 gastroenterostomies, and 1 diagnostic biopsy; 6 bowel resections with lymphadenectomy, 2 en-bloc resections, and 1 by-pass were performed on those with jejuno-ileal tumours. There were complications in 3 patients (18%). General survival was 18 months; in duodenal and jejunal tumours it was 15 months versus 58 in ileal ones (P=.048). Survival was 48 months in the absence of lymph node metastases versus 11 in those with (P=.067). In those tumours infiltrating the retroperitoneum, survival was 15 months compared to 23 when not affected (P=.09).

Conclusions

Curative treatment consists of small bowel resection. Retroperitoneal infiltration was a non-resectability criterion in our series. Ileal location is associated with a better outcome. Advanced stages, lymph node metastases, non-resected cases, and retroperitoneal infiltration tended to be associated with a poor prognosis in our group.

Keywords:
Small bowel adenocarcinoma
Bowel resection
Retroperitoneal infiltration
Resumen
Introducción

El adenocarcinoma primario de intestino delgado es un tumor poco frecuente, con síntomas inespecíficos, lo que condiciona un retraso en el diagnóstico que conlleva peor pronóstico. Evaluamos nuestra experiencia en el manejo de este trastorno.

Material y método

Realizamos un estudio retrospectivo de 17 pacientes diagnosticados de adenocarcinoma primario de intestino delgado, excluyendo los casos en que la afección de intestino delgado era secundaria a un adenocarcinoma de otra localización.

Resultados

Estudiamos a 9 mujeres (53%) y 8 varones (47%) con una media de edad de 61,8 años. Los tumores se originaron en duodeno (8 casos), yeyuno (5) e íleon (4). En los tumores duodenales se realizaron 4 duodenopancreatectomías cefálicas, 3 gastroenteroanastomosis y 1 biopsia diagnóstica; en los tumores yeyunoileales se realizaron 6 resecciones intestinales, 2 resecciones multiorgánicas y una derivación digestiva. Aparecieron complicaciones postoperatorias en 3 pacientes (18%). La supervivencia total fue 18 meses; la de tumores duodenales y yeyunales, 15 meses, frente a 58 de los ileales (p=0,048). En ausencia de metástasis ganglionares, la supervivencia fue 48 meses, frente a 11 con ganglios positivos (p=0,067). En tumores que no infiltraban el retroperitoneo fue 23 meses, frente a 15 en los que sí (p=0,09).

Conclusiones

El tratamiento curativo consiste en la resección del segmento intestinal. La infiltración retroperitoneal fue un criterio de irresecabilidad en nuestros pacientes. La localización en ileon es un factor de buen pronóstico. Los estadios avanzados, las metástasis ganglionares, los casos no resecados y la infiltración del retroperitoneo tienden a asociarse a peor pronóstico en nuestro estudio

Palabras clave:
Adenocarcinoma de intestino delgado
Resección intestinal
Infiltración retroperitoneal
Full text is only aviable in PDF
References
[1.]
M. Bruna, P. Galindo, J.V. Roig, A. Salvador, A. Ismael, A. García Fadrique.
Adenocarcinoma primitivo de intestino delgado con presentación de novo.
Rev Esp Enferm Dig, 98 (2006), pp. 789-790
[2.]
M.H. Kam, C.P. Barben, K.W. Eu, F. Seow-Choen.
Small bowel malignancies: A review of 29 patients at a single centre.
Colorectal Dis, 6 (2004), pp. 195-197
[3.]
G.S. Lien, M. Mori, M. Enjoji.
Primary carcinoma of the small intestine. A clinicopathological and immunohistochemical study.
Cancer, 61 (1988), pp. 316-323
[4.]
V. Palascak-Juif, A.M. Bouvier, J. Cosnes, B. Flourié, O. Bouché, G. Cadiot, et al.
Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo.
Inflamm Bowel Dis, 11 (2005), pp. 828-832
[5.]
K. Chaiyasate, A.K. Jain, L.Y. Cheung, M.J. Jacobs, V.K. Mittal.
Prognostic factors in primary adenocarcinoma of the small intestine: 13-year single institution experience.
World J Surg Oncol, 6 (2008), pp. 1-6
[6.]
S. Guadagni, M. Catarci, T. Ventura, P. Leocata, M. Carboni.
Primary adenocarcinoma arising in the jejunal limb of a Roux en Y esophagojejunostomy. A case report.
Jpn J Clin Oncol, 23 (1993), pp. 59-63
[7.]
J. Rosai.
Adenocarcinoma of the small bowel.
Mosby, (1996),
[8.]
M. Friedrich-Rust, C. Ell.
early stage small bowel adenocarcinoma: review of local endoscopic therapy.
Endoscopy, 37 (2005), pp. 755-759
[9.]
S.M. de Castro, N.T. van Heek, K.F. Kuhlmann, O.R. Busch, G.J. Offerhaus, T.M. van Gulik, et al.
Surgical management of neoplasms of the ampolla of vater: local resection or pancreatoduodenenctomy and prognostic factors for survival.
Surgery, 136 (2004), pp. 994-1002
[10.]
H.W. Bruckner, V.R. Hrehorovich, H.S. Sawhney, S.I. Meeus, A.M. Coopeman.
Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
J Chemother, 18 (2006), pp. 545-548
[11.]
A. Polyzos, G. Kouraklis, A. Giannopoulos, J. Bramis, J.K. Delladetsima, P.P. Sfikakis.
Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients.
J Chemother, 15 (2003), pp. 503-506
[12.]
B. Dabaja, D. Suki, B. Pro, M. Bonnen, J. Ajani.
Adenocarcinoma of the small bowel.
Cancer, 101 (2004), pp. 518-526
[13.]
J.R. Howe, L.H. Karnell, H.R. Menck, C. Scott-Conner.
The American College of Surgeons Commission on cancer and the merican Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995.
Cancer, 86 (1999), pp. 2693-2706
[14.]
Small intestine. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott- Raven; 1997. p. 77–81.
Copyright © 2009. Asociación Española de Cirujanos
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos